Vertex Pharmaceuticals Inc (VRTX.O)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|61||2012||Chairman of the Board, President, Chief Executive Officer|
|51||2017||Chief Operating Officer, Executive Vice President|
|42||2017||Executive Vice President, Chief Legal and Administrative Officer|
|52||2015||Executive Vice President - Global Research, Chief Scientific Officer|
|51||2012||Executive Vice President, Chief Commercial Officer|
- BRIEF-Vertex says FDA sets action date of Feb 28, 2018 for its Tezacaftor/Ivacaftor Combination Treatment
- BRIEF-FDA approves Kalydeco(Ivacaftor) for more than 600 people ages 2 and older with Cystic Fibrosis who have certain residual function mutations
- BRIEF-Vertex interested in early stage assets consistent with CF focus
- Vertex Pharma's quarterly profit beats estimates
- UPDATE 1-Vertex Pharma's quarterly profit beats estimates